ASA Annual Meeting Abstracts

Abstract

The proceedings contain 5174 papers. The topics discussed include: single cell network profiling as a tool to identify AML chemotherapy resistant cell phenotypes under in vivo therapeutic pressure; high expression of lymphoid enhancer-binding factor 1 (LEF1) is a novel, favorable prognostic marker in cytogenetically normal AML and is associated with upregulation of T-lymphoid lineage markers in AML blasts; leukemic stem cell assessment in remission bone marrow of acute myeloid leukemia patients is a new prognostic parameter; expression of apoptosis repressor with caspase recruitment domain (ARC), an antiapoptotic protein, is strongly prognostic in acute myeloid leukemia (AML); deletion of the tumor suppressor gene NF1 is an alternative mechanism for aberrant activation of the RAS pathway and is found in 11% of acute myeloid leukemia; highly phosphorylated foxo3A is an adverse prognostic factor in acute myeloid leukemia; and aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (megaCHOEP) and rituximab for young, high-risk patients with aggressive B-cell lymphoma: results of the megaCHOEP trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).